Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | P4HB | P07237 | 2/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28318559 | 0.83 | NPC1 (0.45) | EGFRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL29576346 | 0.83 | NPC1 (0.45) | EGFRNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL29936890 | 0.80 | SMN1; SMN2 (0.34) | EGFRSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL3074807 | 0.78 | EGFR (0.50) | EGFRTRPV1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL559673 | 0.77 | EGFR (0.48) | EGFRTRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL24857275 | 0.76 | EGFR (0.37) | EGFRP4HB | |
| SCHEMBL276426 | 0.75 | METAP2 (0.55) | EGFRTRPV1RAB9AALDH1A1KDM4E | |
| SCHEMBL276425 | 0.75 | EGFR (0.47) | EGFRTRPV1KDM4ELMNAPIK3CD | |
| SCHEMBL2008884 | 0.75 | CYP3A4 (0.47) | EGFRTRPV1NPC1RAB9AALDH1A1 | |
| SCHEMBL10765869 | 0.75 | EGFR (0.47) | EGFRTRPV1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4305037-B1 | KRAS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-26 | — | — | EP | claimed |
| EP-4655298-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Theras Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-119998275-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-118660880-A | Quinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| WO-2024158778-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-05-02 | — | — | US | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-117500799-A | Substituted fused azines as KRAS G12D inhibitors | 伊莱利利公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20220370416-A1 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | YALE UNIVERSITY | 2022-11-24 | — | — | US | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-6281221-B1 | Substituted 1,3-dioxan-5-ylamino-hererocyclic compounds, processes for their preparation and their use as pest control compositions | HOECHST SCERING AGREVO GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
| CN-1052379-C | Quinazoline derisatives | DOWELANCO (US) | 2000-05-17 | — | — | CN | disclosed |
| EP-0556375-A4 | NEMATICIDAL METHOD | DOWELANCO (US) | 1994-05-18 | — | — | EP | disclosed |
| EP-0556375-A1 | NEMATICIDAL METHOD | DOWELANCO (US) | 1993-08-25 | — | — | EP | disclosed |
| US-5227387-A | QUINOLINE NEMATICIDAL METHOD | DOWELANCO (US) | 1993-07-13 | — | — | US | disclosed |
| WO-1993004583-A1 | NEMATICIDAL METHOD | DOWELANCO (US) | 1993-03-18 | — | — | WO | disclosed |
| CN-1035825-A | Quinazoline derivant | LILLY CO ELI (US) | 1989-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370416-A1 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | EGFR 390/4885TRPV1 4856/4885SMN1; SMN2 2284/4885 |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | KRAS, NRAS, G3BP1 | EGFR 241/4885TRPV1 4512/4885SMN1; SMN2 1542/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | EGFR 950/4885TRPV1 2641/4885SMN1; SMN2 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.